BioSpace News Archive

Marker Therapeutics, Inc. today announced that the Company has been awarded a $2 million grant from the U.S. Food and Drug Administration (FDA) Orphan Products Grants program to support its Phase 2 ARTEMIS trial of its lead multi-tumor-associated antigen (MultiTAA) T cell product candidate, MT-401, in patients with post-transplant acute myeloid leukemia (AML).

ASLAN Pharmaceuticals today announced that two abstracts showcasing new translational data on eblasakimab have been accepted as late-breaking e-posters at the 51st Annual European Society for Dermatological Research (ESDR) Meeting, taking place from September 28 to October 1, 2022.

Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin.

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19.

Bausch + Lomb Corporation released a report of survey results from the company’s first annual Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

Numinus Wellness is pleased to provide an update on the integration of the Novamin acquisition, which completed on June 10, 2022.

Merck (NYSE: MRK), known as MSD outside the United States and Canada , announced that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, IN8bio’s Chief Executive Officer will be participating in a fireside chat at 10:30 a.m. ET tomorrow, Wednesday, September 14, at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

ImmPACT Bio USA , Inc. today announced the appointment of Jonathan Benjamin, M.D., Ph.D. as its chief medical officer.

Innovation Pharmaceuticals today updated shareholders on recent progress by BT BeaMedical Technologies Ltd. to advance its new image guided surgical laser platform for treating previously inoperable cases of epilepsy and for enabling new treatment options for cancer cases in multiple specialties.